Search Results - "Kisa, Renata M" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials

Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials

by Korman, Neil J, Warren, Richard B, Bagel, Jerry, Armstrong, April W, Gooderham, Melinda, Strober, Bruce, Thaçi, Diamant, Morita, Akimichi, Imafuku, Shinichi, Foley, Peter, Sofen, Howard, Zheng, Min, Hippeli, Lauren, Kisa, Renata M, Banerjee, Subhashis, Blauvelt, Andrew
Published in The Journal of dermatological treatment (01.12.2024)

Get full text

Journal Article

Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials

Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials

by Armstrong, April W., Augustin, Matthias, Beaumont, Jennifer L., Pham, Tan P., Hudgens, Stacie, Gordon, Kenneth B., Zhuo, Joe, Becker, Brandon, Zhong, Yichen, Kisa, Renata M., Banerjee, Subhashis, Papp, Kim A.
Published in Dermatology and therapy (01.08.2024)

Get full text

Journal Article

Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials

Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials

by Lebwohl, Mark, Warren, Richard B, Sofen, Howard, Imafuku, Shinichi, Paul, Carle, Szepietowski, Jacek C, Spelman, Lynda, Passeron, Thierry, Vritzali, Eleni, Napoli, Andrew, Kisa, Renata M, Buck, Alex, Banerjee, Subhashis, Thaçi, Diamant, Blauvelt, Andrew
Published in British journal of dermatology (1951) (17.04.2024)

Get full text

Journal Article

Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2)

Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2)

by Strober, Bruce, Blauvelt, Andrew, Warren, Richard B., Papp, Kim A., Armstrong, April W., Gordon, Kenneth B., Morita, Akimichi, Alexis, Andrew F., Lebwohl, Mark, Foley, Peter, Kisa, Renata M., Colston, Elizabeth, Wang, Tao, Banerjee, Subhashis, Thaçi, Diamant
Published in Journal of the European Academy of Dermatology and Venereology (01.08.2024)

Get full text

Journal Article

Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial

Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial

by Thaçi, Diamant, Strober, Bruce, Gordon, Kenneth B., Foley, Peter, Gooderham, Melinda, Morita, Akimichi, Papp, Kim A., Puig, Lluís, Menter, M. Alan, Colombo, Matthew J., Elbez, Yedid, Kisa, Renata M., Ye, June, Napoli, Andrew A., Wei, Lan, Banerjee, Subhashis, Merola, Joseph F., Gottlieb, Alice B.
Published in Dermatology and therapy (01.02.2022)

Get full text

Journal Article

51214 Deucravacitinib efficacy in palmoplantar and fingernail psoriasis by baseline Psoriasis Area and Severity Index (PASI) and baseline body surface area (BSA) in the phase 3 POETYK PSO-1 and PSO-2 trials

51214 Deucravacitinib efficacy in palmoplantar and fingernail psoriasis by baseline Psoriasis Area and Severity Index (PASI) and baseline body surface area (BSA) in the phase 3 POETYK PSO-1 and PSO-2 trials

by Elewski, Boni, Lambert, Jo, Merola, Joseph F., Lebwohl, Mark, Hoyt, Kim, Kisa, Renata M., Banerjee, Subhashis, Scharnitz, Thomas, Cather, Jennifer
Published in Journal of the American Academy of Dermatology (01.09.2024)

Get full text

Journal Article

P096 Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate-to-severe plaque psoriasis: safety profile in older (≥ 65 years) and younger (< 65 years) patients in the phase III POETYK PSO-1, PSO-2 and long-term extension trials

by Kearney, Niamh, Pink, Andrew, Hoyt, Kim, Kisa, Renata M, Banerjee, Subhashis, Rogers, Alexandra, Mullan, Jill, Warren, Richard B
Published in British journal of dermatology (1951) (28.06.2024)

Get full text

Journal Article

43872 Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Scalp, Nail, and Palmoplantar Psoriasis in Japanese Patients With Plaque Psoriasis: Subset Analysis of the Phase 3 POETYK PSO-4 Trial

43872 Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Scalp, Nail, and Palmoplantar Psoriasis in Japanese Patients With Plaque Psoriasis: Subset Analysis of the Phase 3 POETYK PSO-4 Trial

by Imafuku, Shinichi, Okubo, Yukari, Tada, Yayoi, Ohtsuki, Mamitaro, Shao, Yanqiu, Colston, Elizabeth, Kisa, Renata M., Banerjee, Subhashis, Morita, Akimichi
Published in Journal of the American Academy of Dermatology (01.09.2023)

Get full text

Journal Article

51091 Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in plaque psoriasis: 3-year Psoriasis Area and Severity Index (PASI) outcomes in the long-term extension of the phase 3 POETYK PSO-1 and PSO-2 trials

51091 Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in plaque psoriasis: 3-year Psoriasis Area and Severity Index (PASI) outcomes in the long-term extension of the phase 3 POETYK PSO-1 and PSO-2 trials

by Gold, Linda Stein, Banerjee, Subhashis, Colombo, Matthew J., Kisa, Renata M., Berger, Victoria, Hoyt, Kim, Soung, Jennifer, Torres, Tiago, Bhatia, Neal, Glick, Brad P., Kaufmann, Mark D.
Published in Journal of the American Academy of Dermatology (01.09.2024)

Get full text

Journal Article

51109 Efficacy of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in scalp psoriasis by baseline Psoriasis Area and Severity Index (PASI) and baseline body surface area (BSA): A subanalysis of the phase 3 clinical trial data

51109 Efficacy of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in scalp psoriasis by baseline Psoriasis Area and Severity Index (PASI) and baseline body surface area (BSA): A subanalysis of the phase 3 clinical trial data

by Blauvelt, Andrew, Sofen, Howard, Lambert, Jo, Merola, Joseph F., Lebwohl, Mark, Hoyt, Kim, Kisa, Renata M., Banerjee, Subhashis, Scharnitz, Thomas, Crowley, Jeffrey J.
Published in Journal of the American Academy of Dermatology (01.09.2024)

Get full text

Journal Article

43851 Deucravacitinib Long-term Efficacy With Continuous Treatment in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO-1 and POETYK PSO-LTE Trials

43851 Deucravacitinib Long-term Efficacy With Continuous Treatment in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO-1 and POETYK PSO-LTE Trials

by Lebwohl, Mark, Warren, Richard B., Kircik, Leon, Colston, Elizabeth, Hippeli, Lauren, Napoli, Andrew, Kisa, Renata M., Banerjee, Subhashis, Menter, Alan, Thaçi, Diamant, Blauvelt, Andrew
Published in Journal of the American Academy of Dermatology (01.09.2023)

Get full text

Journal Article

P77 Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, vs. placebo and apremilast in moderate-to-severe plaque psoriasis: achievement of absolute Psoriasis Area and Severity Index thresholds in two phase III trials

P77 Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, vs. placebo and apremilast in moderate-to-severe plaque psoriasis: achievement of absolute Psoriasis Area and Severity Index thresholds in two phase III trials

by Warren, Richard B, Lebwohl, Mark, Gooderham, Melinda, Thaci, Diamant, Foley, Peter, Gottlieb, Alice B, Banerjee, Subhashis, Hippeli, Lauren, Kisa, Renata M, Griffiths, Christopher E M
Published in British journal of dermatology (1951) (26.06.2023)

Get full text

Journal Article

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan, and South Korea with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan, and South Korea with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial

by Zhang, Jianzhong, Ding, Yangfeng, Wang, Ping, Li, Linfeng, Pan, Weili, Lu, Yan, Cheng, Hao, Jiang, Xian, Ho, Ji-Chen, Guo, Shuping, Liu, Leona, Chatterjee, Arkendu, Kisa, Renata M, Banerjee, Subhashis
Published in British journal of dermatology (1951) (22.10.2024)

Get full text

Journal Article

35205 Deucravacitinib improves Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis: Results from the phase 3 POETYK PSO-1 and PSO-2 trials

35205 Deucravacitinib improves Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis: Results from the phase 3 POETYK PSO-1 and PSO-2 trials

by Augustin, Matthias, Strober, Bruce, Armstrong, April W., Beaumont, Jennifer, Pham, Tan P., Hudgens, Stacie, Zhuo, Joe, Becker, Brandon, Banerjee, Subhashis, Kisa, Renata M., Papp, Kim
Published in Journal of the American Academy of Dermatology (01.09.2022)

Get full text

Journal Article

13601 BMS-986165, an oral selective TYK2 inhibitor, in the treatment of moderate to severe psoriasis as assessed by the static Physicians Global Assessment/body surface area composite tool, a clinically useful alternative to the Psoriasis Area and Severity Index score

13601 BMS-986165, an oral selective TYK2 inhibitor, in the treatment of moderate to severe psoriasis as assessed by the static Physicians Global Assessment/body surface area composite tool, a clinically useful alternative to the Psoriasis Area and Severity Index score

by Gottlieb, Alice, Strober, Bruce, Thaci, Diamant, Gordon, Kenneth, Ren, Haobo, Kisa, Renata M., Wei, Lan, Banerjee, Subhashis, Merola, Joseph F.
Published in Journal of the American Academy of Dermatology (01.12.2020)

Get full text

Journal Article

Deucravacitinib in moderate to severe plaque psoriasis: liver transaminase results from the phase 3 POETYK PSO program

Deucravacitinib in moderate to severe plaque psoriasis: liver transaminase results from the phase 3 POETYK PSO program

by Lebwohl, Mark, Egeberg, Alexander, Linaberry, Misti, Hoyt, Kim, Banerjee, Subhashis, Kisa, Renata M., Strober, Bruce
Published in Skin (Milwood, N.Y.) (13.03.2023)

Get full text

Journal Article

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: evaluation of lipid parameters in the phase 3 POETYK PSO-1 and PSO-2 trials

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: evaluation of lipid parameters in the phase 3 POETYK PSO-1 and PSO-2 trials

by Lebwohl, Mark, Strober, Bruce, Linaberry, Misti, Hoyt, Kim, Banerjee, Subhashis, Kisa, Renata M., Mehta, Nehal N.
Published in Skin (Milwood, N.Y.) (13.03.2023)

Get full text

Journal Article

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Evaluation of Creatine Phosphokinase Elevations in the Phase 3 POETYK PSO-1 and PSO-2 Trials

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Evaluation of Creatine Phosphokinase Elevations in the Phase 3 POETYK PSO-1 and PSO-2 Trials

by Lebwohl, Mark, Strober, Bruce, Scharnitz, Thomas, Linaberry, Misti, Hoyt, Kim, Banerjee, Subhashis, Kisa, Renata M., Martin, George
Published in Skin (Milwood, N.Y.) (13.11.2023)

Get full text

Journal Article

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline body surface area (BSA) involvement and baseline Psoriasis Area and Severity Index (PASI)

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline body surface area (BSA) involvement and baseline Psoriasis Area and Severity Index (PASI)

by Armstrong, April W., Lebwohl, Mark, Bagel, Jerry, Schlesinger, Todd, Banerjee, Subhashis, Kisa, Renata M., Scharnitz, Thomas, Hoyt, Kim, Strober, Bruce
Published in Skin (Milwood, N.Y.) (13.03.2023)

Get full text

Journal Article

Deucravacitinib Long-term Efficacy With Continuous Treatment in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials

Deucravacitinib Long-term Efficacy With Continuous Treatment in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials

by Thaçi, Diamant, Lebwohl, Mark, Warren, Richard B., Kircik, Leon, Banerjee, Subhashis, Napoli, Andrew, Kisa, Renata M., Linaberry, Misti, Hoyt, Kim, Blauvelt, Andrew
Published in Skin (Milwood, N.Y.) (13.11.2023)

Get full text

Journal Article